EU/3/08/549: Orphan designation for the treatment of malignant mesothelioma

NGR-human tumour necrosis factor

Table of contents


On 3 June 2008, orphan designation (EU/3/08/549) was granted by the European Commission to MolMed S.p.A, Italy, for NGR-human Tumour Necrosis Factor for the treatment of malignant mesothelioma.

Key facts

Active substance
NGR-human tumour necrosis factor
Intended use
Treatment of malignant mesothelioma
Orphan designation status
EU designation number
Date of designation
MolMed S.p.A.
Via Olgettina 58
20132 Milan
Telephone: +39 02 212 771
Telefax: +39 02 212 77 220

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Related content

How useful was this page?

Add your rating